about
Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular diseasePotential Approaches and Recent Advances in Biomarker Discovery in Clear-Cell Renal Cell CarcinomaIdentification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validationFUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression dataData mining of atherosclerotic plaque transcriptomes predicts STAT1-dependent inflammatory signal integration in vascular disease.Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNAComparative screening and validation as a novel tool to identify STAT-specific inhibitors.STAT1-dependent signal integration between IFNγ and TLR4 in vascular cells reflect pro-atherogenic responses in human atherosclerosisSTAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1.Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors.Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases.The interferon-stimulated gene 54 K promoter contains two adjacent functional interferon-stimulated response elements of different strength, which act synergistically for maximal interferon-alpha inducibility.A type I IFN-Flt3 ligand axis augments plasmacytoid dendritic cell development from common lymphoid progenitors.Molecular properties and medical applications of peptide nucleic acids.Gene expression of energy and protein metabolism in hearts of hypertensive nitric oxide- or GSH-depleted mice.STAT1 and IRF8 in Vascular Inflammation and Cardiovascular Disease: Diagnostic and Therapeutic Potential.The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses.STAT1-mediated signal integration between IFNγ and LPS leads to increased EC and SMC activation and monocyte adhesion.Anti-oxidant sensitivity of donor age-related gene expression in cultured fibroblasts.STAT2-directed pathogen responses.Damage-associated molecular pattern activated Toll-like receptor 4 signalling modulates blood pressure in L-NAME-induced hypertension.Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment.Nitric oxide-dependent and nitric oxide-independent transcriptional responses to high shear stress in endothelial cells.Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease.Fibronectin is a hypoxia-independent target of the tumor suppressor VHL.In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls Type I and Type II IFN Responses.Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDsThyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidatesDirect Inhibition of IRF-Dependent Transcriptional Regulatory Mechanisms Associated With Disease.Phenotypic plasticity of Escherichia coli upon exposure to physical stress induced by ZnO nanorods.Transcriptome-based identification of pro- and antioxidative gene expression in kidney cortex of nitric oxide-depleted ratsIncreased SOCS expression in peripheral blood mononuclear cells of end stage renal disease patients is related to inflammation and dialysis modalityIFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cellsSignal Integration of IFN-I and IFN-II With TLR4 Involves Sequential Recruitment of STAT1-Complexes and NFκB to Enhance Pro-inflammatory TranscriptionQ95559110
P50
Q26750725-459A1EE3-7476-4964-811A-2233321040BCQ26777900-CE96A783-30D3-40EF-8B3B-1152E5623827Q28543632-86CCDE0E-E7DA-4EC1-BBA2-802B156849E3Q30711138-C20B881E-8D4E-434A-A562-C22A2FFA212BQ30848049-71EDF844-ED49-4E5F-A18A-4C9614229808Q33709786-4D71ADF6-1984-4A32-A8B7-32343FB255D9Q35237252-1A7FC40D-AFD7-4FA4-8E63-CAAC1169C112Q35493777-55C9B2CD-55ED-4DC1-98A7-DBDCEA4AD227Q35494968-6BE811BD-AF84-40CE-B823-056E6E791906Q35689954-9F8378EE-5C4A-4975-9273-4FCA1BD821F4Q35828729-1198FC00-A7BD-4F64-8835-EA8A89DB17D8Q36744099-F8BA5956-8550-4B9D-B0B1-258A28D7B1C0Q37322150-5A36A714-7794-472A-9239-C628429A6308Q38207122-226D19E7-E14C-4585-8A1D-0A5A706C132BQ38326658-629673D6-626A-43B9-B075-DF82D0E47B44Q38647432-609CE1CF-BC1E-400D-BF00-77993BB73248Q38800260-24F9F702-1C25-4DF3-9D86-21F87C3051CBQ39586956-99BCE840-B9EA-46A1-B975-DD33C63FD430Q40263163-903CF513-8AC2-4027-A2FD-5DD553E8CFB8Q42558105-3EF8FF12-92C5-481F-A184-88349B062F5FQ43797072-C35D3A2D-C797-41C4-8EDB-6C596A43C7D8Q44790592-544136E8-EB56-4FC9-8C31-D93E2020FA38Q45256396-FF6252A8-F6A3-4334-9127-41CFDD2B99A2Q46461923-073D8D6F-632F-489C-B66B-543BAA4C2BF7Q48035055-8597B584-FB52-4B27-9805-5C67EFFEDED7Q54630289-69E37B90-190A-45A8-A9A8-7E660A4F81DCQ54976472-27027DED-7CB4-48C0-AA9F-E90333CCEDE0Q57072670-1E27BD25-0BB0-4B07-ADA1-24E484B0D7FFQ58796314-4B8CABAA-DDAE-45AA-85ED-21CAF0187612Q64969424-F0E7CA04-3E3C-4CE1-B33B-7B427C956370Q67311480-28A03A0B-BEB5-492B-AE34-77CA0CD96B75Q79260166-C54CE7FC-6C1F-4A5A-A9BB-7F26A422A0B6Q82762801-F4E344DC-6B29-43C1-8BFA-D63EEE225FCDQ84258129-DD24A4CB-DAE7-4861-B839-FC87013E3AD2Q92971130-ADA05B67-2D87-409E-973D-A79D8ED1326EQ95559110-F703448D-373D-471C-A89E-DB7267BB01B5
P50
description
researcher
@en
wetenschapper
@nl
name
H A Bluyssen
@en
H A Bluyssen
@nl
type
label
H A Bluyssen
@en
H A Bluyssen
@nl
prefLabel
H A Bluyssen
@en
H A Bluyssen
@nl
P106
P31
P496
0000-0002-4568-6259